PharmaVentures Podcast Series, Edition 7
Listen as Ben Jacoby, Regulatory Expert, talks with Adrian Dawkes about the transition to the new regulations in Europe and UK:
- Can existing products continue to be sold?
- What will global manufacturers need to do?
- What is the impact for companion diagnostics being used alongside drugs in clinical trials?
- How is the environment in Great Britain different, and what does this mean for innovators?
- What’s the impact for patients?
A rare opportunity to hear from one of the most experienced regulatory advisors in this important space.
About the Presenter:
Adrian Dawkes is a Managing Director at PharmaVentures and has been with the company since 2007. Adrian has led multiple consultancy, licensing and M&A mandates.
During his professional career, Adrian has significant multi-discipline expertise spanning research and development through to sales, marketing and business development. Adrian has over 30 years’ experience in the pharmaceutical, biotechnology and consultancy services sectors. Adrian holds a BSc in Biochemistry and a PhD in Immunochemistry.
About the Interviewee:
Ben Jacoby is an experienced regulatory consultant who has worked with clients in the diagnostic, medical device and pharmaceutical industries to help them bring innovative products to market. He provides regulatory and strategic guidance on EU, UK and US issues to clients.
Ben has worked on European and UK medical device regulation.
Core competencies include: technical files, Clinical studies; EU and UK legislation including IVD’s, companion diagnostics and medical devices; EU legislative requirements for instruments; and classification of devices. With more than 25 years of experience in regulatory affairs, he was European-authorised representative at Ortho-Clinical Diagnostics (a Johnson & Johnson company at the time).
Ben has a PhD in Biochemistry from the University of London.